Evaluation of HMGB1 as possible marker via breast organoid cultures research

Ciaramella,Vincenza; Carrese,Barbara; Coppola,Luigi; Smaldone,Giovanni; D'Aiuto,Massimiliano; Mossetti,Gennaro; Soricelli,Andrea; Salvatore,Marco

doi:10.3892/or.2025.8939

Evaluation of HMGB1 as possible marker via breast organoid cultures research

Authors:
- Vincenza Ciaramella
- Barbara Carrese
- Luigi Coppola
- Giovanni Smaldone
- Massimiliano D'Aiuto
- Gennaro Mossetti
- Andrea Soricelli
- Marco Salvatore
View Affiliations

Affiliations: IRCCS SYNLAB SDN, I-80146 Naples, Italy, Clinica Villa Fiorita, I-81031 Aversa, Italy, Pathological Anatomy Service, Maria Rosaria Clinic, Pompei, I-80045 Naples, Italy
Published online on: July 1, 2025 https://doi.org/10.3892/or.2025.8939
Article Number: 106
Copyright: © Ciaramella et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

High mobility group box 1 (HMGB1) is a non‑histone protein widely expressed in the nucleus of mammalian cells, and it can be released by both immune and tumor cells. In the extracellular context HMGB1 can act as a proinflammatory mediator and boosting cancer progression. High HMGB1 mRNA expression levels are usually observed in various malignant diseases, including breast cancer (BC). Several studies have demonstrated the potential clinical value of HMGB1 in BC diagnosis and therapy. The present data, using in vitro protocols and molecular technologies, demonstrated the presence of HMGB1 in organoids derived from patients with BC with significantly elevated expression correlating with poorer prognosis. By blocking the activity of HMGB1 protein, cell cycle arrest and induction of apoptosis was observed in ex vivo 3D organoids, suggesting a potential antitumor effect. The localization by immunofluorescence, of HMGB1, β‑catenin and NF‑kB in organoids and the subsequent inhibition of the entire molecular pathway by switching off HMGB1 signaling suggests that there is a crosstalk between these molecules demonstrating their involvement in inflammation and inflammation‑associated diseases such as cancer. The current results aim to investigate the role of HMGB1 in BC progression and find innovative applications based on HMGB1 as a therapeutic target and early disease biomarker.

View Figures

View References

1	Zeng X, Liu C, Yao J, Wan H, Wan G, Li Y and Chen N: Breast cancer stem cells, heterogeneity, targeting therapies and therapeutic implications. Pharmacol Res. 163:1053202021. View Article : Google Scholar : PubMed/NCBI
2	Leone I, Santoro J, Soricelli A, Febbraro A, Santoriello A and Carrese B: Triple-negative breast cancer EVs modulate growth and migration of normal epithelial lung cells. Int J Mol Sci. 25:58642024. View Article : Google Scholar : PubMed/NCBI
3	Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, Vignat J, Gralow J, Cardoso F, Siesling S and Soerjomataram I: Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast. 66:15–23. 2022. View Article : Google Scholar : PubMed/NCBI
4	Obeagu E and Obeagu G: Breast cancer: A review of risk factors and diagnosis. Medicine (Baltimore). 103:e369052024. View Article : Google Scholar : PubMed/NCBI
5	Bianchi ME, Beltrame M and Paonessa G: Specific recognition of cruciform DNA by nuclear protein HMG1. Science. 243:1056–1059. 1989. View Article : Google Scholar : PubMed/NCBI
6	Starkova T, Polyanichko A, Artamonova T, Tsimokha A, Tomilin A and Chikhirzhina E: Structural characteristics of High-mobility group proteins HMGB1 and HMGB2 and their interaction with DNA. Int J Mol Sci. 24:35772023. View Article : Google Scholar : PubMed/NCBI
7	Chen R, Zou J, Kang R and Tang D: The redox protein High-Mobility group box 1 in cell death and cancer. Antioxid Redox Signal. 39:569–590. 2023. View Article : Google Scholar : PubMed/NCBI
8	Lv G, Yang M, Gai K, Jia Q, Wang Z, Wang B and Li X: Multiple functions of HMGB1 in cancer. Front Oncol. 14:13841092024. View Article : Google Scholar : PubMed/NCBI
9	He S, Cheng J, Feng X, Yu Y, Tian L and Huang Q: The dual role and therapeutic potential of High-mobility group box 1 in cancer. Oncotarget. 8:64534–64550. 2017. View Article : Google Scholar : PubMed/NCBI
10	Cai Z and Liu Q: Cell cycle regulation in treatment of breast cancer. Adv Exp Med Biol. 1026:251–270. 2017. View Article : Google Scholar : PubMed/NCBI
11	Chen G, Ward MF and Wang H: Extracellular HMGB1 as a proinflammatory cytokine. J Interferon Cytokine Res. 24:329–33. 2004. View Article : Google Scholar : PubMed/NCBI
12	Dong Y, Ming B and Dong L: The role of HMGB1 in rheumatic diseases. Front Immunol. 13:8152572022. View Article : Google Scholar : PubMed/NCBI
13	Oh H, Choi A, Seo N, Lim J, You J and Chung Y: Protective effect of glycyrrhizin, a direct HMGB1 inhibitor, on Post-contrast acute kidney injury. Sci Rep. 11:156252021. View Article : Google Scholar : PubMed/NCBI
14	Jain R, Hussein M, Pierce S, Martens C, Shahagadkar P and Munirathinam G: Oncopreventive and oncotherapeutic potential of licorice triterpenoid compound glycyrrhizin and its derivatives: Molecular insights. Pharmacol Res. 178:1061382022. View Article : Google Scholar : PubMed/NCBI
15	Chang H, Chen S, Wu C, Lu C and Yen G: Glycyrrhizin attenuates the process of Epithelial-to-Mesenchymal transition by modulating HMGB1 initiated novel signaling pathway in prostate cancer cells. J Agric Food Chem. 67:323–3332. 2019. View Article : Google Scholar
16	Mastroleo I: Post-trial obligations in the declaration of helsinki 2013: Classification, reconstruction and interpretation. Dev World Bioeth. 16:80–90. 2016. View Article : Google Scholar : PubMed/NCBI
17	Lee GY, Kenny PA, Lee EH and Bissell MJ: Three-dimensional culture models of normal and malignant breast epithelial cells. Nat Methods. 4:359–365. 2007. View Article : Google Scholar : PubMed/NCBI
18	Della Corte CM, Barra G, Ciaramella V, Di Liello R, Vicidomini G, Zappavigna S, Luce A, Abate M, Fiorelli A, Caraglia M, et al: Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures. J Exp Clin Cancer Res. 38:2532019. View Article : Google Scholar : PubMed/NCBI
19	DeRose YS, Gligorich KM, Wang G, Georgelas A, Bowman P, Courdy SJ, Welm AL and Welm BE: Patient-derived models of human breast cancer: Protocols for in vitro and in vivo applications in tumor biology and translational medicine. Curr Protoc Pharmacol. Chapter 14: Unit14. 232013.PubMed/NCBI
20	Mollica L, De Marchis F, Spitaleri A, Dallacosta C, Pennacchini D, Zamai M, Agresti A, Trisciuoglio L, Musco G and Bianchi ME: Glycyrrhizin binds to High-mobility group box 1 protein and inhibits its cytokine activities. Chem Biol. 14:431–441. 2007. View Article : Google Scholar : PubMed/NCBI
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
22	Tang Z, Kang B, Li C, Chen T and Zhang Z: GEPIA2: An enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 47:W556–W560. 2019. View Article : Google Scholar : PubMed/NCBI
23	Pourbarkhordar V, Rahmani S, Roohbakhsh A, Hayes AW and Karimi G: Melatonin effect on breast and ovarian cancers by targeting the PI3K/Akt/mTOR pathway. IUBMB Life. 76:1035–1049. 2024. View Article : Google Scholar : PubMed/NCBI
24	Guangyao L, Yang M, Gai K, Jia Q, Wang Z, Wang B and Li X: Multiple functions of HMGB1 in cancer. Front Oncol. 14:13841092024. View Article : Google Scholar : PubMed/NCBI
25	Li C, Tang Z, Zhang W, Ye Z and Liu F: GEPIA2021: Integrating multiple deconvolution-based analysis into GEPIA. Nucleic Acids Res. 49:W242–W246. 2021. View Article : Google Scholar : PubMed/NCBI
26	Dudhatra G, Mody S, Awale M, Patel H, Modi C, Kumar A, Kamani D and Chauhan B: A Comprehensive review on pharmacotherapeutics of herbal bioenhancers. ScientificWorldJournal. 2012:6379532012. View Article : Google Scholar : PubMed/NCBI
27	Pucci B, Kasten M and Giordano A: Cell cycle and apoptosis. Neoplasia. 2:291–299. 2000. View Article : Google Scholar : PubMed/NCBI
28	Wang CM, Jiang M and Wang HJ: Effect of NF-κB inhibitor on high-mobility group protein B1 expression in a COPD rat model. Mol Med Rep. 7:499–502. 2013. View Article : Google Scholar : PubMed/NCBI
29	Kim M, Park S and Lee D: Glycyrrhizin as a nitric oxide regulator in cancer chemotherapy. Cancers (Basel). 13:57622021. View Article : Google Scholar : PubMed/NCBI
30	Dholakia J, Scalise CB, Katre AA, Goldsberry WN, Meza-Perez S, Randall TD, Norian LA, Novak L and Arend RC: Sequential modulation of the Wnt/β-catenin signaling pathway enhances Tumor-intrinsic MHC I expression and tumor clearance. Gynecol Oncol. 164:170–180. 2022. View Article : Google Scholar : PubMed/NCBI
31	Scaffidi P, Misteli T and Bianchi ME: Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 418:191–195. 2022. View Article : Google Scholar : PubMed/NCBI